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Introduction
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A staggering one third of all humans are affected
by insomnia. Sleep-related complaints are also disproportionately high in prevalence in medical practice. This
malady, which was once thought to be an innocuous
annoyance, is now known to impair normal human function, to cause a variety of medical and psychiatric disorders, and even to limit lifespan. For medical practitioners,
therefore, the proper identi¿cation, clinical evaluation,
and effective management of insomnia are of signi¿cant
importance.
In this book, we take a systematic approach in
informing the primary care practitioner in the evaluation
and management of insomnia. In Chapter 2, we begin
with a foundation in normal sleep neurophysiology. The
past few decades have seen a tremendous advance in our
understanding of the central underpinnings of sleep and
wakefulness. We now know that this seemingly quiescent
state is the product of a complex array of interactions that
produce a balance between wake-promoting systems on
the one hand, governed by norepinephrine, serotonin,
dopamine, acetylcholine, and histamine, and sleep-promoting systems on the other hand, governed by GABA
and galanin and under the circadian influence of the
hormone melatonin. Newly discovered neurotransmitters,
the orexins/hypocretins, play a critical role in maintaining
an orderly transition between these two states.
In Chapters 3 through 6, we present the most
recent diagnostic guidelines for insomnia. We explore
key developments in clarifying the pathophysiology of
insomnia, and explain how these have led to an evolution
of our view of the relationship between co-occurring
insomnia and medical/psychiatric disorders from a model
of unidirectional causality to one of autonomous disorders interacting in a bidirectional fashion. We also delve
into an in-depth review of the many consequences of this
disorder.
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In Chapters 7 and 8, we present some of the most
important aspects of insomnia for clinical practitioners,
ie, its evaluation and management. We stress the importance of a thorough of¿ce-based evaluation, and present
guidelines for this endeavor based on the most recent
practice parameter statements. We emphasize the importance of treatment that is focused on underlying cause,
as opposed to the uninformed entry into symptomatic
management. In Chapters 9 through 11, we explore the
many available pharmacologic agents for the treatment
of insomnia and provide an evidence-based approach
in their selection and use. Whereas GABA receptor
agonists have traditionally dominated the therapeutic
armamentarium, we review novel and investigational
agents with mechanisms traversing the receptor systems
that are involved in the control of sleep and arousal, such
as selective histamine H1 receptor antagonists, selective
melatonin receptor agonists, and dual orexin receptor
antagonists. “Natural” compounds enjoy a signi¿cant
allure by virtue of their widespread availability and the
perception that they are safer than prescription medications for insomnia. We explore the vast array of such
products utilized for sleep-related complaints and provide
empirical data to guide practitioners through the morass
of claims regarding the bene¿ts of these agents. Although
less widely utilized than pharmacologic agents, cognitive
and behavioral therapies are of clear bene¿t in insomnia.
We explore the principles underlying these techniques
and guidelines in their implementation. We also review
exciting new evidence demonstrating the lasting bene¿t
of these therapies for extended periods of time following
termination of treatment.
Throughout the book, we are guided by our main
goal of providing practitioners with clinically relevant,
evidence-based, and state-of-the-art information in the
evaluation and management of insomnia. We have made
a concerted attempt to ensure that our reviews are consistent with professional guidelines to the extent that current
knowledge permits. Nevertheless, we remind our readers
that scienti¿c discovery is ongoing. Since the publication of this textbook, certain guidelines and standards
for treatment may already have changed. In addition, in
16

clinical practice, medications may be used for indications
and at doses that are not covered by the package label.
Therefore we advise readers to consult the peer-reviewed
literature, as well as product labels, to obtain the most
up-to-date information regarding recommended doses,
safety pro¿les, indications, and other guidelines. Useful
resources include the FDA website (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm) and FDA
safety alerts at http://www.fda.gov/Safety/Recalls/default.
htm.
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